Imunon’s (IMNN) Buy Rating Reaffirmed at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Imunon (NASDAQ:IMNN) in a report published on Wednesday morning,Benzinga reports. They currently have a $29.00 price objective on the stock.

Separately, HC Wainwright restated a “buy” rating and issued a $12.00 price objective on shares of Imunon in a research report on Thursday, December 19th.

Imunon Stock Performance

Shares of Imunon stock opened at $0.89 on Wednesday. Imunon has a 52-week low of $0.51 and a 52-week high of $3.65. The company’s 50 day moving average price is $0.89 and its 200-day moving average price is $0.96. The stock has a market capitalization of $12.83 million, a price-to-earnings ratio of -0.47 and a beta of 2.03.

Institutional Trading of Imunon

A hedge fund recently raised its stake in Imunon stock. Geode Capital Management LLC raised its position in shares of Imunon, Inc. (NASDAQ:IMNN) by 10.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 139,505 shares of the company’s stock after buying an additional 13,570 shares during the quarter. Geode Capital Management LLC owned about 0.96% of Imunon worth $133,000 at the end of the most recent quarter. Institutional investors and hedge funds own 4.47% of the company’s stock.

About Imunon

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.